This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (26)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Glaucoma  • Ophthalmological Disorders, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Dosing, Efficacy, and Safety Evaluation of a Novel Compound for Glaucoma Management

Robert A. Laibovitz, MD; Amanda M. VanDenburgh, PhD, MBA; Carlos Felix, MS; Robert David, MD; Amy Batoosingh, BA; Allan Rosenthal, PhD; Janet Cheetham, PharmD

Arch Ophthalmol. 2001;119:994-1000.

Objective  To compare the safety and efficacy of the ocular hypotensive lipid AGN 192024 (Lumigan) with those of timolol.

Methods  A 30-day, randomized, investigator-masked, clinical trial involving 100 patients with elevated intraocular pressure (IOP). Study medications were instilled topically. Doses of 0.003%, 0.01%, or 0.03% AGN 192024 were given once daily for 3 weeks then twice daily for 1 week, and vehicle control or 0.5% timolol was given twice daily for 4 weeks. Mean change in IOP from baseline was the primary efficacy variable. Safety parameters included adverse events, hyperemia grading, laser flare meter analysis, heart rate, and blood pressure.

Results  Timolol and all 3 concentrations of AGN 192024 lowered IOP from baseline (P<.001). A dosage of 0.03% AGN 192024 once daily lowered IOP significantly more than timolol (P.02) at every study visit except day 21 (P = .053) and provided better diurnal IOP control. Twice-daily dosing of AGN 192024 provided no clinically significant benefit over once-daily dosing. All treatment regimens were safe and well tolerated, with no clinically significant effects on heart rate or blood pressure and no between-group differences in the incidence of adverse events. The only significant ocular safety finding with AGN 192024 was a dose-related mild increase in conjunctival hyperemia.

Conclusions  Of the 3 concentrations tested, 0.03% AGN 192024 once daily had the best therapeutic profile. AGN 192024 was safe and well tolerated, and it provided superior ocular hypotensive efficacy and diurnal IOP control compared with timolol in patients with ocular hypertension and glaucoma.

From Eye Research Associates, Austin, Tex (Dr Laibovitz); and Allergan Inc, Ophthalmology Clinical Research, Irvine, Calif (Drs VanDenburgh, David, Rosenthal, and Cheetham, Mr Felix, and Ms Batoosingh). Dr Laibovitz was a paid evaluator and does not have any financial or proprietary interest in AGN 192024 or the study sponsor, Allergan Inc. Drs VanDenburgh, David, Rosenthal, and Cheetham, Mr Felix, and Ms Batoosingh are employees of Allergan Inc.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2001;119(7):1092.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacological Characterization of a Novel Antiglaucoma Agent, Bimatoprost (AGN 192024)
Woodward et al.
J. Pharmacol. Exp. Ther. 2003;305:772-785.
ABSTRACT | FULL TEXT  

A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension
Whitcup et al.
Br J Ophthalmol 2003;87:57-62.
ABSTRACT | FULL TEXT  

One-Year, Randomized Study Comparing Bimatoprost and Timolol in Glaucoma and Ocular Hypertension
Higginbotham et al.
Arch Ophthalmol 2002;120:1286-1293.
ABSTRACT | FULL TEXT  

An Accurate Comparison of Bimatoprost's Efficacy and Adverse Effects
Robin and VanDenburgh
Arch Ophthalmol 2002;120:999-1000.
FULL TEXT